This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Enliven Therapeutics, Inc.
Selected Condensed Consolidated Financial Information
(in thousands, except per share data)
(unaudited)
Statements of
Operations Three Months Ended September 30, Nine Months Ended September 30,
------------------------------------------------ ------------------------------------------------
2024 2023 2024 2023
----------------------- ----------------------- ----------------------- -----------------------
Operating
expenses:
Research and
development $ 21,258 $ 19,606 $ 60,054 $ 46,669
General and
administrative 5,810 4,642 17,604 14,131
Total operating
expenses 27,068 24,248 77,658 60,800
----------------------- ----------------------- ----------------------- -----------------------
Loss from operations (27,068) (24,248) (77,658) (60,800)
Other income
(expense), net 3,912 3,479 11,814 8,586
Net loss $ (23,156) $ (20,769) $ (65,844) $ (52,214)
======================= ======================= ======================= =======================
Net loss per share,
basic and diluted $ (0.48) $ (0.51) $ (1.43) $ (1.55)
Weighted-average
shares outstanding,
basic and
diluted 48,267 41,031 46,137 33,665
Balance Sheets September 30, December 31,
2024 2023
----------------------- -----------------------
Assets
Current assets:
Cash, cash equivalents and marketable securities $ 291,834 $ 253,148
Restricted cash 54 54
Prepaid expenses and other current assets 5,109 2,949
Contingent value right asset -- 10,000
----------------------- -----------------------
Total current assets 296,997 266,151
Property and equipment, net 549 742
Operating lease right-of-use assets 81 320
Deferred offering costs 563 563
Other long-term assets 7,240 4,091
Total assets $ 305,430 $ 271,867
======================= =======================
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 1,019 $ 532
Accrued expenses and other current liabilities 16,008 15,362
Contingent value right liability -- 10,000
----------------------- -----------------------
Total current liabilities 17,027 25,894
Long-term liabilities -- 67
----------------------- -----------------------
Total liabilities 17,027 25,961
----------------------- -----------------------
Stockholders' equity 288,403 245,906
Total liabilities and stockholders' equity $ 305,430 $ 271,867
======================= =======================
View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-reports-third-quarter-financial-results-and-provides-a-business-update-302304281.html
SOURCE Enliven Therapeutics, Inc.
/CONTACT: Investors, ir@enliventherapeutics.com; Media, media@enliventherapeutics.com
(END) Dow Jones Newswires
November 13, 2024 16:05 ET (21:05 GMT)
Comments